Beta-arrestin mutants

Patent metadata

Field	Value
Publication number	US-12522647-B2
Application number	US-202017425095-A
Country	US
Kind code	B2
Filing date	Jan 21, 2020
Priority date	Jan 22, 2019
Publication date	Jan 13, 2026
Grant date	Jan 13, 2026

Abstract

The invention relates to the field of arrestin mutants, especially mutants of beta-arrestin, a complex of the mutant beta-arrestin and a G-protein-coupled receptor (GPCR), and a vector encoding the mutant beta-arrestin.

First claim

The invention claimed is:

1 . A mutant human arrestin-3 wherein: (a) said mutant stabilizes a complex of GPCR and said arrestin-3 mutants, (b) there is increased recruitment of ligand to GPCRs as compared to a parent beta-arrestin, wherein said parent beta-arrestin is a naturally occurring human arrestin-3, and (c) independently at least two amino acids are mutated as compared to a parent beta-arrestin, wherein said parent beta-arrestin is a naturally occurring human arrestin-3, and wherein: (i) a first of said at least two mutated amino acids is located at an amino acid position which corresponds to 1386 in human arrestin-3 of SEQ ID NO: 1; and (ii) a second of said at least two mutated amino acids is located at an amino acid position which corresponds to T299 in the human arrestin-3 of SEQ ID NO: 1 and (d) wherein the mutant human arrestin-3 is mutated by an exchange of an amino acid by a different amino acid, the different amino acid being selected from the group consisting of glycine, 2-aminobutyric acid, allo-isoleucine, isoleucine, leucine, norleucine, norvaline, and valine.

2 . The mutant human arrestin-3 according to claim 1 , wherein in said mutant human arrestin-3 at least three amino acids are independently mutated as compared to said parent beta-arrestin.

3 . The mutant human arrestin-3 according to claim 2 , wherein the third amino acid of said at least three mutated amino acids is located at an amino acid position which corresponds to an amino acid position selected from the group consisting of R166, D298, and R393 in the human arrestin-3 of SEQ ID NO: 1.

4 . The mutant human arrestin-3 according to claim 1 , wherein said parent beta-arrestin has the amino acid sequence of SEQ ID NO: 1.

5 . The mutant human arrestin-3 according to claim 1 , wherein independently at least two and at most 40 amino acid positions are mutated as compared to said parent beta-arrestin.

6 . The mutant human arrestin-3 according to claim 1 , wherein independently at least two and no more than 20 amino acid positions, or 10 amino acid positions, or 5 amino acid positions are mutated as compared to said parent beta-arrestin.

7 . The mutant human arrestin-3 according to claim 1 , wherein independently at least two and at most 4 amino acid positions, or at least two and at most 3 amino acid positions, are mutated as compared to said parent beta-arrestin.

8 . The mutant human arrestin-3 according to claim 1 , wherein the different amino acid is selected from the group consisting of glycine, leucine, isoleucine, and valine.

9 . A mutant human arrestin-3 which comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, wherein (a) said mutant stabilizes a complex of GPCR and said arrestin-3 mutants and (b) there is increased recruitment of ligand to GPCRs as compared to a parent beta-arrestin, wherein said parent beta-arrestin is a naturally occurring human arrestin-3.

10 . A complex of the mutant human arrestin-3 of claim 1 and a G protein-coupled receptor (GPCR).

11 . The complex according to claim 10 , wherein the GPCR is a beta-adrenergic receptor (βAR).

12 . A vector encoding the mutant human arrestin-3 according to claim 1 .

13 . A complex of the mutant human arrestin-3 of claim 9 and a G protein-coupled receptor (GPCR).

14 . The complex according to claim 13 , wherein the GPCR is a beta-adrenergic receptor (BAR).

15 . A vector encoding the mutant human arrestin-3 according to claim 9 .

Assignees

• Scherrer Inst Paul
• Interax Biotech Ag

Inventors

• Meger Benoit
• Ostermaier Martin Konrad
• Berger Philipp
• Zimmermann Mirjam
• Waldhoer Maria

Classifications

• C07K14/723 Primary

  G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor · CPC title

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title

• G01N2333/726

  G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH · CPC title

• G01N33/74 Primary

  involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title